Latest Breaking News On - Durham based humacyte - Page 1 : comparemela.com
NCBiotech Awards $1 9M in Grants, Loans in Latest Quarter | North Carolina Biotechnology Center
ncbiotech.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ncbiotech.org Daily Mail and Mail on Sunday newspapers.
Top 10 U S Biopharma Clusters
genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
Key partnership with Fresenius
Humacyte was founded in 2004, and the Biotechnology Center provided it a $150,000 Small Business Research Loan in 2006.
Since then Humacyte has raised nearly $480 million, including a $150 million equity investment from Fresenius Medical Care, the world’s leading provider of products and services for patients with renal diseases and for surgical care centers.
“Humacyte is a world-class regenerative medicine company developing bioengineered tissues to treat unmet medical needs,” said Vivian Doelling, Ph.D., NCBiotech’s vice president of Emerging Company Development. “The company has been a trailblazer in these advanced and readily available technologies. It’s one of the best examples of North Carolina-based ingenuity and medical advancement.”
Humacyte Set to Go Public, Raise $175 Million from Top-tier Investors
Durham-based Humacyte, a regenerative medicine company that received start-up support from the North Carolina Biotechnology Center 15 years ago, is going public in a novel deal that will give it a market capitalization of $1.1 billion.
Humacyte and Alpha Healthcare Acquisition Corp., a special purpose acquisition company (SPAC) based in New York, have signed a business-combination agreement to take Humacyte public, along with a $175M PIPE financing agreement.
“We are very pleased to have support from top-tier investors and access to the U.S. capital markets following the closing of this proposed transaction, which will leave Humacyte well-capitalized to provide first-in-class therapies to treat several life-threatening diseases,” Laura Niklason, M.D., Ph.D., founder and chief executive officer of Humacyte, said in a prepared statement.